Market Research Logo

Head and Neck Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Immunotherapies and Increasing Prevalence to Drive the Market

Head and Neck Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Immunotherapies and Increasing Prevalence to Drive the Market

Summary


Head and neck squamous cell carcinoma is the sixth most common cancer, and its incidence is growing. The term head and neck cancer (HNC) refers to a number of malignancies that usually begin in the squamous cells (90% of HNCs) that line the moist, mucosal surfaces inside the head and neck. These cancers develop inside the mouth, the nose and the throat.

HNCs can also initially develop in the salivary glands; however, these are relatively uncommon. Salivary glands contain many different types of cells that can become cancerous, so there are many different types of salivary gland cancers. Relatively rare HNC malignancies include acinic cell adenocarcinoma of the parotid gland (a form of salivary gland cancer), eye cancer (retinoblastoma), and ear cancer.

The annual incidence of HNCs worldwide is more than 0.5 million cases, with around 0.3 million related deaths occurring each year. In terms of the initial site of development, around 44% of HNCs involve the oral cavity, more than 30% the larynx, and around 25% the pharynx. The incidence of tobacco-related HNC is decreasing, but the incidence of cancer due to the human papillomavirus (HPV) continues to increase at a rate of 2-4% per year. HNC is most common in the middle aged, with a peak incidence rate between the ages of 55 and 64, and a median age of diagnosis of 62.

The HNC market is characterized by a small selection of marketed drug options, consisting of chemotherapies, targeted therapies (anti-EGFR), and immunotherapies (PD1/PD-L1 inhibitor). Historically, cytotoxic chemotherapies have made up the bulk of the HNC market. Little competition currently exists in the HNC market, leaving an area of considerable opportunity for interested newcomers. Currently, four targeted therapies are available in the APAC HNC market, which are Erbitux, BIOMAb EGFR, Opdivo and Keytruda. The remainder of this market is composed of generics. Recent additions to the market have highlighted that the treatment landscape is diversifying and becoming less reliant on chemotherapy options.

With the approval of Keytruda in Australia, and Opdivo in Australia, South Korea and Japan, there has been an increase in targeted therapy options. Additionally avelumab (a PD-L1 inhibitor) is likely to be approved in APAC countries at the end of the forecast period, as it is currently undergoing Phase III trials in Japan, Australia and South Korea. A number of mAbs are in development in HNC for the inhibition of various different pathways and signaling systems. Many companies are following a strategy of developing products with similar mechanisms of action to those of existing products already approved in either HNC or other oncology indications. EGFR and PD-1/PD-L1 are the most commonly addressed targets in the current pipeline.

However, there are also many innovative products in the HNC pipeline, which reflects a deepening scientific understanding of the underlying pathophysiology of HNC and the growing list of molecules that have been implicated in the initiation and progression of the disease.

The report Head and Neck Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Immunotherapies and Increasing Prevalence to Drive the Market helps you to -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the HNC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the HNC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict HNC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the HNC deals landscape by analyzing trends in licensing and co-development deals.
Scope
  • The HNC Asia-Pacific market will be valued at $424.5m in 2023, growing from $265.9m in 2016 at a CAGR of 6.9%.
  • How will immune checkpoint inhibitors such as Opdivo, Keytruda and Imfinzi contribute to growth?
  • What effect will patent expirations of branded therapies have on market value?
  • The HNC pipeline is large and diverse, with an strong presence of mAbs and targeted therapies.
  • What are the common targets and mechanisms of action of pipeline therapies?
  • Will the pipeline address unmet needs such as the lack of targeted therapies available for locally advanced HNC patients?
  • What implications will the increased focus on targeted therapies have on the future of HNC treatment?
  • Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
  • How have the late-stage therapies performed in clinical trials?
  • How would the approval of Keytruda, Opdivo and Bavencio to treat locally advanced HNC patients affect the competitive landscape, with no immunotherapy currently available to address this patient subset?
  • The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
  • How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
  • How could changes in risk factors such as population age, tobacco use (both smoked and smokeless) and alcohol consumption influence the market?
  • Licensing deals are the most common form of strategic alliance in HNC, with total deal values ranging from under $10m to over $1 billion.
  • How do deal frequency and value compare between target families and molecule types?
  • What were the terms and conditions of key licensing deals?
Reasons to buy
  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the HNC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the HNC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict HNC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the HNC deals landscape by analyzing trends in licensing and co-development deals.


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Disease Introduction
    • Epidemiology
      • Table Figure 1: HNC Therapeutics Market, Australia, Estimated Age-Specific Incidence and Mortality Rates for HNC, by Sex, 2017
      • Table Figure 2: HNC Therapeutics Market, Australia, Five-Year Relative Survival from HNC by Sex, 1984– 2013
    • Symptoms
      • Table Symptoms of HNC, 2017
      • Table Symptoms of HNC Metastasis, 2017
    • Etiology and Pathophysiology
      • Etiology
      • Pathophysiology
        • Table Common Mutations in HNC Metastasis, 2017
      • Biomarkers/Targets of Interest
    • Diagnosis
    • Disease Stages
      • Table TNM Classification of Lip, Oral Cavity, and Oropharyngeal Cancers, 2017
      • Table TNM Classification of the Larynx, 2017
      • Table TNM Classification of the Hypopharynx, 2017
      • Table TNM Classification of Salivary Gland Cancers, 2017
      • Table TNM Classification of Nasopharyngeal Cancers, 2017
      • Table Stage Grouping for HNC (Excluding Nasopharyngeal and Thyroid Cancer), 2017
      • Table Stage Grouping for Nasopharyngeal Cancer, 2017
    • Prognosis
    • Treatment Guidelines and Options
      • Table Figure 3: HNC Therapeutics Market, Treatment Algorithm for HNC (Excluding Nasopharyngeal and Thyroid Cancer)
      • Table Figure 4: HNC Therapeutics Market, Treatment Algorithm for Nasopharyngeal Cancer and Thyroid Cancer
      • Surgery and Radiation Therapy
      • Chemotherapy
      • Targeted Therapies
  • Marketed Products
    • Overview
    • Chemotherapies
      • TS-1 (tegafur plus gimeracil plus oteracil) – Taiho Pharma
      • Cisplatin
      • Docetaxel
      • Fluorouracil (5-FU)
      • Methotrexate
    • Epidermal Growth Factor Receptor Targeted Therapies
      • Erbitux (cetuximab) – Eli Lilly/Merck KGaA
      • BIOMAb EGFR (nimotuzumab) – Biocon/Biotech Pharmaceutical Co.
    • Programmed Cell Death Protein 1/Programmed Death Ligand 1 Immune Checkpoint Inhibitors
      • Opdivo (nivolumab) – Bristol-Myers Squibb
      • Keytruda (pembrolizumab) – Merck & Co.
    • Comparative Efficacy and Safety of Marketed Products
      • Table Figure 5: HNC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products
  • Pipeline Analysis
    • Overview
    • Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
      • Table Figure 6: HNC Therapeutics Market, Global, Pipeline, 2017
    • Pipeline by Molecular Target
      • Table Figure 7: HNC Therapeutics Market, Global, Pipeline by Molecular Target, 2017
      • Table Figure 8: HNC Therapeutics Market, Pipeline by Molecular Target and Stage of Development, 2017
    • Promising Pipeline Candidates
      • Imfinzi (durvalumab) – MedImmune
        • Table Figure 9: HNC Therapeutics Market, APAC, Imfinzi Forecast ($m), 2019–2023
        • Table Figure 10: HNC Therapeutics Market, APAC, Durvalumab plus Tremelimumab Forecast ($m), 2019– 2023
      • Gilotrif/Giotrif/Xovoltib (afatinib) – Boehringer Ingelheim
        • Table Figure 11: HNC Therapeutics Market, APAC, Gilotrif/Giotrif/Xovoltib Forecast ($m), 2020–2023
      • Bavencio (avelumab) – Merck KgaA/Pfizer
    • Comparative Efficacy and Safety of Pipeline Products
      • Table Figure 12: HNC Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products
    • Product Competitiveness Framework
      • Table Figure 13: HNC Therapeutics Market, Competitor Matrix for HNC Marketed and Pipeline Products, 2017
  • Clinical Trial Analysis
    • Failure Rate
      • Overall Failure Rate
        • Table Figure 14: HNC Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006–2016
      • Failure Rate by Phase and Molecule Type
        • Table Figure 15: HNC Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006–2016
      • Failure Rate by Phase and Molecular Target
        • Table Figure 16: HNC Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006–2016
    • Clinical Trial Size
      • Patient Enrollment per Product by Molecule Type and Stage of Development
        • Table Figure 17: HNC Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006–2016
      • Patient Enrollment per Product by Molecular Target and Stage of Development
        • Table Figure 18: HNC Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2006–2016
      • Patient Enrollment per Trial by Molecule Type and Stage of Development
        • Table Figure 19: HNC Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2006–2016
      • Patient Enrollment per Trial by Molecular Target and Stage of Development
        • Table Figure 20: HNC Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2006–2016
    • Clinical Trial Duration
      • Trial Duration by Molecule Type and Stage of Development
        • Table Figure 21: HNC Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006–2016
      • Trial Duration by Molecular Target and Stage of Development
        • Table Figure 22: HNC Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2006–2016
    • Summary of Clinical Trial Metrics
      • Table Figure 23: HNC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
      • Table Figure 24: HNC Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
  • Multi-scenario Forecast
    • Overview
    • Asia-Pacific Market
      • Table Figure 25: HNC Therapeutics Market, APAC, Treatment Patterns (`000), 2016–2023
      • Table Figure 26: HNC Therapeutics Market, APAC, Market Size ($m), 2016–2023
    • India
      • Treatment Usage Patterns
        • Table Figure 27: HNC Therapeutics Market, India, Treatment Patterns (`000), 2016–2023
      • Annual Cost of Therapy
        • Table Figure 28: HNC Therapeutics Market, India, Annual Cost of Therapy ($), 2016–2023
      • Market Size
        • Table Figure 29: HNC Therapeutics Market, India, Market Size ($m), 2016–2023
    • China
      • Treatment Usage Patterns
        • Table Figure 30: HNC Therapeutics Market, China, Treatment Patterns (`000), 2016–2023
      • Annual Cost of Therapy
        • Table Figure 31: HNC Therapeutics Market, China, Annual Cost of Therapy ($), 2016–2023
      • Market Size
        • Table Figure 32: HNC Therapeutics Market, China, Market Size ($m), 2016–2023
    • Australia
      • Treatment Usage Patterns
        • Table Figure 33: HNC Therapeutics Market, Australia, Treatment Patterns (`000), 2016–2023
      • Annual Cost of Therapy
        • Table Figure 34: HNC Therapeutics Market, Australia, Annual Cost of Therapy ($), 2016–2023
      • Market Size
        • Table Figure 35: HNC Therapeutics Market, Australia, Market Size ($m), 2016–2023
    • South Korea
      • Treatment Usage Patterns
        • Table Figure 36: HNC Therapeutics Market, South Korea, Treatment Patterns (`000), 2016–2023
      • Annual Cost of Therapy
        • Table Figure 37: HNC Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016–2023
      • Market Size
        • Table Figure 38: HNC Therapeutics Market, South Korea, Market Size ($m), 2016–2023
    • Japan
      • Treatment Usage Patterns
        • Table Figure 39: HNC Therapeutics Market, Japan, Treatment Patterns (`000), 2016–2023
      • Annual Cost of Therapy
        • Table Figure 40: HNC Therapeutics Market, Japan, Annual Cost of Therapy ($), 2016–2023
      • Market Size
        • Table Figure 41: HNC Therapeutics Market, Japan, Market Size ($m), 2016–2023
  • Drivers and Barriers
    • Drivers
      • Increasing Incidence of HNC
      • Adoption of Immuno-oncology Therapies in the HNC Treatment Algorithm
      • Launch of Premium Priced Pipeline Products
      • Increasing Usage of High Premium Priced Combination Therapies
      • Diversified Healthcare Reform and Insurance System to Boost Market Growth
    • Barriers
      • Usage of Surgical Therapies at Early Stage Reduces Drug Treatment Rate
      • Patent Expiration of Branded Therapies to Affect HNC Market Growth
      • Lack of Development of Pipeline Products for Locally Advanced HNC
      • High Prices of Therapeutics, Lack of Reimbursement and Penetration of Generics to Slow Down Market Growth in China and India
      • Drug Pricing Reforms
  • Deals and Strategic Consolidations
    • Licensing Deals
      • Deals by Region and Value
        • Table Figure 42: HNC Therapeutics Market, Global, Licensing Deals by Region and Value, 2006–2017
      • Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
        • Table Figure 43: HNC Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006–2017
      • Deal Value by Stage of Development, Molecule Type, and Molecular Target
        • Table Figure 44: HNC Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006–2017
        • Table Figure 45: HNC Therapeutics Market, Global, Licensing Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006–2017
        • Table Figure 46: HNC Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006–2017
      • Key Licensing Deals
        • Table HNC Therapeutics Market, Global, Licensing Deals Valued Above $10m, 2006–2017
    • Co-development Deals
      • Deals by Region and Value
        • Table Figure 47: HNC Therapeutics Market, Global, Co-development Deals by Region, 2006–2017
      • Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
        • Table Figure 48: HNC Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006– 2017
      • Deal Value by Stage of Development, Molecule Type, and Molecular Target
        • Table Figure 49: HNC Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006–2017
        • Table Figure 50: HNC Therapeutics Market, Global, Co-development Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006–2017
        • Table Figure 51: HNC Therapeutics Market, Global, Co-development Deals by by Molecular Target and Aggregate Deal Value ($m), 2006–2017
      • Key Co-development Deals
        • Table HNC Therapeutics Market, Global, Co-development Deals Valued Above $10m, 2006–2017
  • Appendix
    • All Pipeline Drugs by Stage of Development
      • Discovery
        • Table HNC Therapeutics Market, Global, All Pipeline Products, Discovery, 2017
      • Preclinical
        • Table HNC Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
      • IND/CTA-filed
        • Table HNC Therapeutics Market, Global, All Pipeline Products, IND/CTA-filed, 2017
      • Phase I
        • Table HNC Therapeutics Market, Global, All Pipeline Products, Phase I, 2017
      • Phase II
        • Table HNC Therapeutics Market, Global, All Pipeline Products, Phase II, 2017
      • Phase III
        • Table HNC Therapeutics Market, Global, All Pipeline Products, Phase III, 2017
    • Market Forecasts to 2023
      • Asia-Pacific
        • Table HNC Therapeutics Market, APAC, Market Forecast, 2016–2023
      • India
        • Table HNC Therapeutics Market, India, Market Forecast, 2016–2023
      • China
        • Table HNC Therapeutics Market, China, Market Forecast, 2016–2023
      • Australia
        • Table HNC Therapeutics Market, Australia, Market Forecast, 2016–2023
      • South Korea
        • Table HNC Therapeutics Market, South Korea, Market Forecast, 2016–2023
      • Japan
        • Table HNC Therapeutics Market, Japan, Market Forecast, 2016–2023
    • Bibliography
    • Abbreviations
    • Research Methodology
      • Secondary Research
      • Marketed Product Profiles
      • Late-Stage Pipeline Candidates
      • Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
      • Product Competitiveness Framework
      • Pipeline Analysis
      • Forecasting Model
      • Deals Data Analysis
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report